SHP2/HDAC-IN-1 is an allosteric dual inhibitor of SHP2 and HDAC (IC50 = 20.4 nM for SHP2; 25.3 nM for HDAC1). It triggers antitumor immune responses by activating T cells, enhancing antigen presentation, and promoting cytokine secretion. It can be used in cancer immunotherapy research.